Key Highlights

  • Loss per share was USD 0.18 against an estimate of a USD 0.21 loss.
  • Net loss was USD 3.55 million, compared with USD 3.96 million.
  • Research and development expense was USD 1.83 million, compared with USD 2.31 million.
  • Cash was USD 2.34 million at September 30, 2026.

Traws Pharma (NASDAQ:TRAW) reported a third quarter 2026 net loss of USD 3.55 million, compared with USD 3.96 million in the prior-year quarter. Net loss per share was USD 0.18, compared with USD 0.34, against an estimate of a USD 0.21 loss.

The company describes itself as a clinical stage biopharmaceutical company dedicated to developing novel therapies that target critical threats to human health in respiratory viral diseases. The filing reports no Revenue for the third quarter.

Third Quarter Results

Research and development expense was USD 1.83 million, compared with USD 2.31 million, and general and administrative expense was USD 1.77 million, compared with USD 1.74 million. Total operating expenses were USD 3.60 million, compared with USD 4.06 million.

The change in Fair Value of the Warrant Liability was USD 37 thousand, compared with USD 3 thousand. Net loss attributable to common stockholders was USD 3.06 million, compared with USD 3.04 million. Weighted average common shares outstanding were 17,044,826, compared with 8,818,859.

Nine-Month Results

For the nine months ended September 30, 2026, the company reported no revenue, compared with USD 2.79 million in the prior-year period. Research and Development expense was USD 9.04 million and general and administrative expense was USD 7.28 million, and other Operating Income was USD 1.41 million.

The net loss was USD 14.86 million, compared with Net Income of USD 16.61 million in the prior-year period, which included a change in fair value of the warrant liability of USD 26.66 million. Net loss per share was USD 0.86, compared with net income per share of USD 1.56 basic and USD 1.53 diluted.

Balance Sheet and Going Concern Disclosure

Cash was USD 2.34 million at September 30, 2026, compared with USD 3.82 million at December 31, 2025. Tax incentive and other receivables were USD 2.20 million, compared with USD 3.79 million, and total Assets were USD 7.52 million, compared with USD 10.62 million.

Total liabilities were USD 9.65 million, compared with USD 11.25 million. Shares outstanding were 15,375,595, compared with 9,067,774. The filing discloses substantial doubt about the company's ability to continue as a going concern and describes a need for substantial additional financing.

Net cash used in Operating Activities for the nine months was USD 12.56 million, compared with USD 15.43 million in the prior-year period. Total current assets were USD 4.98 million, compared with USD 7.98 million at December 31, 2025.

The accumulated Deficit was USD 654.85 million, compared with USD 639.98 million, and total stockholders' deficit was USD 2.13 million, compared with USD 629 thousand. The filing states that the company has an accumulated deficit of approximately USD 654.85 million.

Traws Pharma Q3 2026 Earnings: Key Takeaways

Traws Pharma reported a third quarter 2026 net loss of USD 3.55 million and a loss per share of USD 0.18. Cash was USD 2.34 million at September 30, 2026.